Tempest Therapeutics, Inc. (TPST)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 70K 140K 210K Q1 '14: 0 Q2 '14: 0 Q3 '14: 0 Q4 '14: 0 Q1 '15: 15K Q2 '15: 30K Q3 '15: 75K Q4 '15: 157K Q1 '16: 146K Q2 '16: 189K Q3 '16: 197K Q4 '16: 121K Q1 '17: 63K Q2 '17: 84K Q3 '17: 56K Q4 '17: 91K Q1 '18: 67K Q2 '18: 81K Q3 '18: 55K Q1 '14 Q4 '14 Q3 '15 Q2 '16 Q1 '17 Q4 '17 Q3 '18

Gross Profit Quarterly

-1.5M -1M -500K 0 500K 1M 1.5M Q1 '14: 0 Q2 '14: 0 Q3 '14: 0 Q4 '14: 0 Q1 '15: -20K Q2 '15: -86K Q3 '15: -865K Q4 '15: -1M Q1 '16: -1M Q2 '16: -1M Q3 '16: -1.4M Q4 '16: -1.3M Q1 '17: -206K Q2 '17: -190K Q3 '17: 27K Q4 '17: -127K Q1 '18: -45K Q2 '18: 27K Q3 '18: 11K Q1 '14 Q4 '14 Q3 '15 Q2 '16 Q1 '17 Q4 '17 Q3 '18

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '16: -19M Q4 '16: -22.4M Q1 '17: -14.6M Q2 '17: -17.9M Q3 '17: -9.4M Q4 '17: -42.4M Q1 '18: -4.4M Q2 '18: -5M Q3 '18: -7.8M Q4 '18: -9.7M Q1 '19: -10.7M Q2 '19: -10.2M Q3 '19: -11.8M Q4 '19: -12.8M Q1 '20: -12.1M Q2 '20: -5.2M Q3 '20: 5.4M Q4 '20: -34.3M Q1 '21: -5.1M Q2 '21: -6.8M Q3 '21: -7.7M Q4 '21: -7.3M Q1 '22: -8.2M Q2 '22: -8.8M Q3 '22: -8.8M Q4 '22: -8.9M Q1 '23: -7.6M Q2 '23: -7.5M Q3 '23: -6.6M Q4 '23: -7.5M Q1 '24: -8M Q2 '24: -9.6M Q3 '24: -10.6M Q4 '24: -13.9M Q1 '25: -10.9M Q2 '25: -8M Q3 '25: -3.6M Q4 '25: -4.1M Q1 '26: -27.7M Q2 '26: -5.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '16: -19.3M Q4 '16: -22.6M Q1 '17: -14.9M Q2 '17: -18.2M Q3 '17: -9.4M Q4 '17: -42.1M Q1 '18: -4.3M Q2 '18: -4.8M Q3 '18: -7.5M Q4 '18: -10.5M Q1 '19: -10.4M Q2 '19: -9.9M Q3 '19: -11.6M Q4 '19: -12.7M Q1 '20: -12M Q2 '20: -5.2M Q3 '20: -5.4M Q4 '20: -4.3M Q1 '21: -5.4M Q2 '21: -7.1M Q3 '21: -8.1M Q4 '21: -28.3M Q1 '22: -8.5M Q2 '22: -9.2M Q3 '22: -8.9M Q4 '22: -9.1M Q1 '23: -7.6M Q2 '23: -7.6M Q3 '23: -6.8M Q4 '23: -7.5M Q1 '24: -7.9M Q2 '24: -9.6M Q3 '24: -10.6M Q4 '24: -13.8M Q1 '25: -10.9M Q2 '25: -7.9M Q3 '25: -3.5M Q4 '25: -4M Q1 '26: -27.7M Q2 '26: -5.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

0 600K 1.2M 1.8M Q1 '14: 0 Q2 '14: 0 Q3 '14: 0 Q4 '14: 0 Q1 '15: 35K Q2 '15: 116K Q3 '15: 940K Q4 '15: 1.2M Q1 '16: 1.2M Q2 '16: 1.2M Q3 '16: 1.6M Q4 '16: 1.4M Q1 '17: 269K Q2 '17: 274K Q3 '17: 29K Q4 '17: 218K Q1 '18: 112K Q2 '18: 54K Q3 '18: 44K Q1 '14 Q4 '14 Q3 '15 Q2 '16 Q1 '17 Q4 '17 Q3 '18

Operating Cash Flow Quarterly

-18M -12M -6M 0 6M 12M 18M Q3 '16: -15.4M Q4 '16: -15M Q1 '17: -15.2M Q2 '17: -12.1M Q3 '17: -10.3M Q4 '17: 17.2M Q1 '18: -5M Q2 '18: -4.7M Q3 '18: -4.7M Q4 '18: -9.2M Q1 '19: -10.6M Q2 '19: -10.6M Q3 '19: -8.4M Q4 '19: -11.7M Q1 '20: -10.2M Q2 '20: 40K Q3 '20: -4.6M Q4 '20: -4.3M Q1 '21: -6.3M Q2 '21: 127K Q3 '21: -11.8M Q4 '21: -8M Q1 '22: -7.1M Q2 '22: -8.4M Q3 '22: -9.1M Q4 '22: -6.5M Q1 '23: -8.3M Q2 '23: -6.4M Q3 '23: -6.5M Q4 '23: -6.2M Q1 '24: -7.2M Q2 '24: -5.5M Q3 '24: -10.2M Q4 '24: -10.1M Q1 '25: -8M Q2 '25: -8.4M Q3 '25: -6.8M Q4 '25: -3.6M Q1 '26: -7.6M Q2 '26: -2.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-18M -12M -6M 0 6M 12M 18M Q2 '16: -16.4M Q3 '16: -15.6M Q4 '16: -16.5M Q1 '17: -15.3M Q2 '17: -12.1M Q3 '17: -10.3M Q1 '18: -5M Q2 '18: -4.7M Q3 '18: -4.7M Q4 '18: -9.2M Q1 '19: -10.6M Q2 '19: -10.8M Q3 '19: -8.4M Q4 '19: -11.7M Q1 '20: -10.2M Q2 '20: 29K Q3 '20: -4.6M Q4 '20: -4.3M Q1 '21: -6.3M Q2 '21: 57K Q3 '21: -11.8M Q4 '21: -8M Q1 '22: -7.1M Q2 '22: -8.5M Q3 '22: -9.2M Q4 '22: -6.8M Q1 '23: -8.3M Q2 '23: -6.5M Q3 '23: -6.5M Q4 '23: -6.2M Q1 '24: -7.4M Q2 '24: -5.8M Q3 '24: -10.2M Q4 '24: -10.2M Q1 '25: -8M Q2 '25: -8.4M Q3 '25: -6.8M Q4 '25: -3.6M Q1 '26: -7.6M Q2 '26: -2.8M Q2 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 6M 12M 18M Q3 '20: 521.4K Q1 '21: 507.4K Q2 '21: 925.4K Q3 '21: 6.7M Q1 '22: 7.2M Q2 '22: 11.6M Q3 '22: 13.6M Q1 '23: 13.8M Q2 '23: 14.1M Q3 '23: 14.1M Q1 '24: 1.7M Q2 '24: 1.7M Q3 '24: 2M Q1 '25: 3.4M Q2 '25: 3.8M Q3 '25: 4.4M Q1 '26: 10.9M Q2 '26: 15.2M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-450.00 -300.00 -150.00 0.00 150.00 300.00 450.00 Q3 '16: -2.71 Q4 '16: -2.60 Q1 '17: -2.22 Q2 '17: -2.11 Q3 '17: -1.83 Q4 '17: -321.81 Q1 '18: -327.39 Q2 '18: -333.70 Q3 '18: -344.05 Q4 '18: -17.58 Q1 '19: -12.36 Q2 '19: -6.28 Q3 '19: 3.46 Q4 '19: -3.26 Q1 '20: -3.13 Q2 '20: -13.81 Q3 '20: -24.16 Q4 '20: -41.03 Q1 '21: -50.93 Q2 '21: -47.14 Q3 '21: -37.13 Q4 '21: -7.47 Q1 '22: 1.90 Q2 '22: 8.74 Q3 '22: 9.29 Q4 '22: -3.26 Q1 '23: -2.63 Q2 '23: -2.38 Q3 '23: -2.20 Q4 '23: -1.91 Q1 '24: -5.98 Q2 '24: -10.96 Q3 '24: -15.80 Q4 '24: -19.48 Q1 '25: -18.02 Q2 '25: -14.57 Q3 '25: -10.04 Q4 '25: -6.64 Q1 '26: -6.01 Q2 '26: -4.28 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.